New combo therapy aims to shrink EGFR lung tumors
NCT ID NCT04141644
First seen May 23, 2026 · Last updated Jun 11, 2026 · Updated 4 times
Summary
This study tests whether adding the immunotherapy drug ipilimumab to the standard targeted therapy osimertinib is safe and effective for people with a specific type of advanced lung cancer (EGFR-mutated NSCLC). About 24 adults whose cancer is stable on osimertinib will receive the combination. The main goals are to check for side effects and see if tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER WITH MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (DISORDER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.